Research progress of antibody–drug conjugates in gynecologic cancer.
| Autor: | Xu, Dongdong, Chen, Zhe-Sheng, Peng, Xuanwei, Lin, Zhongqiu, Lu, Huaiwu |
|---|---|
| Předmět: |
THERAPEUTIC use of monoclonal antibodies
CERVIX uteri tumors ANTINEOPLASTIC agents OVARIAN tumors IMMUNOTHERAPY DECISION making FEMALE reproductive organ tumors MONOCLONAL antibodies ENDOMETRIAL tumors DRUG approval CANCER chemotherapy DRUG efficacy BIOSIMILARS EPIDERMAL growth factor receptors DRUG resistance PHARMACODYNAMICS |
| Zdroj: | Holistic Integrative Oncology; 8/29/2024, Vol. 3 Issue 1, p1-13, 13p |
| Abstrakt: | Gynecologic cancer is a critical concern in the field of women's health, and traditional treatment methods have demonstrated limited efficacy for certain advanced and recurrent gynecologic cancers. In recent years, antibody–drug conjugate (ADC) therapy, as an emerging targeted approach, has gained increasing attention as a research hotspot. This review aims to elucidate the structure and mechanism of ADC drugs and explore their application and clinical research progress in gynecologic cancers such as ovarian cancer, cervical cancer, and endometrial cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink